U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07360938) titled 'Drug Interaction Potential of Pro-Inflammatory Conditions' on Jan. 06.
Brief Summary: Pro-inflammatory cytokines, which are elevated in pro-inflammatory disease states (e.g., type II diabetes mellitus [T2DM], irritable bowel diseases [IBD], and end stage renal disease [ESRD]) have been shown to inhibit hepatic drug-metabolizing enzymes, including members of the cytochrome P450 (CYP) family, and drug transporters; resultantly, pro-inflammatory diseases have been demonstrated to increase the exposure and potential for adverse drug events with co-administered CYP and drug transporter substrates. However, the clinical relevance of pro-i...